Biostock - Connecting Innovation And Capital company information, Employees & Contact Information

Bioretec withdraws financial targets Biostock

AI from Google and Yale reveals hidden tumors Biostock

Genovis signs million-dollar order with global pharmaceutical company Biostock

SynAct Pharma's CBO: “We are pioneering the future of inflammation care” Biostock

PharmNovo one step closer to clinical trial after CTA approval Biostock

Hansa Biopharma strengthens position after successful year Biostock

Bavarian Nordic takeover battle intensifies as top shareholder rejects higher bid Biostock

Spago's CEO comments on the Proof-of-Concept milestone Biostock

Lead Biologics reports promising results Biostock

The pharmaceutical sector is riding a USD 61,6 billion R&D wave Biostock

BioInvent’s oncolytic virus showcased at ESMO Biostock

Annexin's Q3: Establishment of Medical Advisory Board and focus on ophthalmology Biostock

BioInvent comments on the new chapter for BI-1206 Biostock

AdjuTec Pharma’s CEO: “We must restore antibiotics” Biostock

The news sweep Wednesday 22 October Biostock

Carbiotix: "We are trailblazers" Biostock

News roundup Tuesday, October 14 Biostock

PHI comments on expansion into veterinary IVF Biostock

Segulah Medical is flagging for Swedish medtech – institutions must step forward Biostock

Curasight to enter clinical trials with uTREAT in brain cancer Biostock

PILA PHARMA partners with Gubra for preclinical obesity trials Biostock

AcuCort strengthens management ahead of next growth phase Biostock

PHI strengthens presence in Asia through Gaia Bioscience Biostock

Alzinova comments on the FDA Fast Track Designation Biostock

Lipum gears up with new CFO – one month into the assignment Biostock

Xspray Pharma's CEO: "XS003 shows that we are building a powerhouse – Dasynoc is just the beginning" Biostock

Alzinova secures short-term financing – CEO comments Biostock

BioInvent secures FDA Fast Track Designation for BI-1808 Biostock

Corline strengthens position after billion-dollar deal – cash replenished ahead of US launch Biostock

From gene therapy to investment company: What happened to CombiGene? Biostock

Xspray Pharma CEO: "Hope to launch end of 2025" Biostock

Oxcia also receives ODD approval from EMA Biostock

Green Light for Higher Doses in Isofol’s Arfolitixorin Study Biostock

Immunovia receives preliminary reimbursement for PancreaSure test Biostock

FDA introduces fast track for drugs of national importance Biostock

Alzinova takes the next step towards a phase II study in the US Biostock

Senzime launches integration with Mindray Biostock

DNB // Back Bay takes the pulse of the life science market Biostock

Tailwind and emission will take Oncopeptides into the black Biostock

The giants flee the UK – AstraZeneca and Eli Lilly come second Biostock

Sanofi Ventures doubles down on early-stage biotech with $625M boost Biostock

Biosergen advances antifungal drug with strong Q1 results Biostock

Bioretec updates commercialization status of RemeOs DrillPin Biostock

NextCell’s CEO comments on long-term potential Biostock

Alligator presents preclinical data for ATOR-4066 Biostock

Saniona’s new CMO: “More deals are definitely on the horizon” Biostock

Promising 4-month data from Cereno's Expanded Access Program Biostock

Xspray Pharma signs license agreement with Handa Therapeutics Biostock

Kardium's Globe catheter with CHS coating receives FDA approval Biostock

Roche may reconsider $50 billion investment in the US Biostock

US and Japan in trade deal with record investments Biostock

GTCR acquires Zentiva for EUR 4,1 billion Biostock

Cinclus Pharma starts phase III study Biostock

BioStock’s article series on drug development: The Success of Orphan Drug Designation Biostock

SynAct Pharma secures patent for resomelagon in combination with MTX Biostock

Saniona's CEO comments on the billion-dollar deal Biostock

Orexo shows promising data for intranasal semaglutide Biostock

Female alopecia – new solutions on the horizon Biostock

Sedana Medical receives FDA approval for early access in the US Biostock

Drug development – ​​The challenges Biostock

Saniona’s new CFO: “More deals are definitely on the horizon” Biostock

Biosergen advances BSG005 antifungal drug candidate trial Biostock

CLS not significantly affected by tariffs Biostock

Saniona strengthens the US executive team with three industry veterans Biostock

Saniona’s CSO: “We are on track with SAN2219” Biostock

Sprint Biosciences CEO on new issue and business development Biostock

Respiratorius continues to improve its offering Biostock

Saniona's CFO on the strategy to reach clinical milestones Biostock

SEK 122 million gives Biovica the power to scale up globally Biostock

Saniona comments on their new chapter in epilepsy treatment Biostock

BioStock Investor Meeting, September 14 Biostock

Respiratorius conducts pre-IND meeting and decides on rights issue Biostock

Lobbying battle in the White House over Chinese medicines Biostock

Alzinova is pursuing partnerships at BIO Biostock

Saniona’s CEO responds to investors’ questions Biostock

BioArctic and Eisai bring Leqembi closer to home with new subcutaneous version Biostock

3 out of 4 respond to BioNTech and BMS lung cancer candidate Biostock

Abliva’s VP of Clinical Operations on the screening achievement Biostock

The solution in TO1 will accelerate the launch of EndoDrill GI Biostock

BioStock Global Forum 2024 Biostock

SynAct Pharma’s resomelagon under clinical evaluation for dengue Biostock

Biosergen takes aim at climate-driven fungal infections Biostock

Strong first half of the year for Elicera Biostock

Mölnlycke invests 115 million USD in US expansion Biostock

Biosergen scales up for future wins Biostock

OssDsign changes CEO for increased US focus Biostock

Integrum collapses after Osteocentric withdraws Biostock

SynAct Pharma strengthens its strategy and financial position in Q2 Biostock

Enzymatica’s results published in The Journal of Physiology Biostock

Cantargia prepares for the future with Otsuka agreement and new leadership Biostock

BioInvent prepares for a data-rich 2025 Biostock

Former FDA chief at Pfizer draws criticism Biostock

Curasight enters clinical trials with uTREAT in brain cancer Biostock

Otsuka Pharmaceutical acquires Cantargia's CAN10 program in a deal worth over USD 600 million Biostock

Biosergen’s CEO: “These findings open up new possibilities” Biostock

Lundbeck makes huge bid for Longboard Biostock

Health & Wealth #18 | Live with Claus Johansen, Global Health Invest | Global Forum 2025 Biostock

Promising preliminary results for Elicera Therapeutics’ CAR T-cell study Biostock

Medivir comments on the patent approval Biostock

Sanofi invests over $20 billion in the US Biostock